High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database-Reference-Cited by-同舟云学术

High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database

Published:2023-04-20 Issue:8 Volume:22 Page:685-696
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Ma Pan¹²^ORCID,Tian Hao³^ORCID,Shi Qiuling²^ORCID,Liu Ruixiang¹,Zhang Yi³,Qi Xiaowei³^ORCID,Chen Yongchuan¹^ORCID

Affiliation:

1. Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, China

2. State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China

3. Department of Breast and Thyroid Surgery, Southwest Hospital, The First Affiliated Hospital of Army Medical University, Chongqing, China

Funder

Chongqing Clinical Pharmacy KeySpecialties Construction Project

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2204228

Reference47 articles.

1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

2. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

3. Gastric cancer

4. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

5. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region;Frontiers in Pharmacology;2024-08-06

2. Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations;Advanced Drug Delivery Reviews;2024-08

3. Molecular targets for metastasis-directed therapy in malignant tumors;Bulletin of Siberian Medicine;2024-07-10

4. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database;Frontiers in Pharmacology;2024-05-03

5. Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials;Gynecologic Oncology;2024-03